CD5789 cream vehicle

CD5789 cream vehicle is the inactive topical formulation used as a placebo control in clinical trials investigating trifarotene (CD5789) for the treatment of lamellar ichthyosis. Developed by Mayne Pharma in collaboration with Galderma, it was used in a Phase 2 randomized, double-blind study (NCT03735394) to provide a baseline for comparing the safety and efficacy of the active retinoid cream in patients with autosomal recessive ichthyosis with lamellar scale. The vehicle contains the same excipients as the active drug product but lacks the active pharmaceutical ingredient, trifarotene, which is a selective retinoic acid receptor gamma (RARγ) agonist. The clinical program for this indication was terminated in 2021 following a futility analysis.

Other names

Trifarotene cream vehicle